The fallacies of the lipid hypothesis

References

• Ravnskov U. The questionable role of saturated and polyunsaturated fatty acids in cardiovascular disease. J Clin Epidemiol. 1998; 51: 443–60
   PubMed Web of Science ®Google Scholar
• Krauss RM, Blanche PJ, Rawlings RS, Fernstrom HS, Williams PT. Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia. Am J Clin Nutr. 2006; 83: 1025–31
   PubMed Web of Science ®Google Scholar
• Ravnskov U. The Cholesterol Myths. New Trends Publishing, Washington 2000
   Google Scholar
• Roselli della Rovere G, Lapolla A, Sartore G, Rossetti C, Zambon S, Minicuci N, et al. Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study. Nutr Metab Cardiovasc Dis. 2003; 13: 46–51
   PubMed Web of Science ®Google Scholar
• Bellomo G, Lippi G, Saronio P, Reboldi G, Verdura C, Timio F, et al. Inflammation, infection and cardiovascular events in chronic hemodialysis patients: a prospective study. J Nephrol. 2003; 16: 245–51
   PubMed Web of Science ®Google Scholar
• Ravnskov U. High cholesterol may protect against infections and atherosclerosis. Q J Med. 2003; 96: 927–34
   Google Scholar
• Ravnskov U. Is atherosclerosis caused by high cholesterol. Q J Med 2002; 95: 397–403
   Google Scholar
• Mölgaard J, von Schenk H, Kuusi T, Holme I, Lassvik C, Taskinen MR, et al. Plasma lipoprotein abnormalities and apolipoptotein E phenotypes in intermittent claudication. A multivariate analysis of randomly selected subjects. Nutr Metab Cardiovasc Dis. 1996; 6: 114–23
   Web of Science ®Google Scholar
• Miettinen TA, Gylling H. Mortality and cholesterol metabolism in familial hypercholesterolemia. Arteriosclerosis 1988; 8: 163–7
   PubMedGoogle Scholar
• Neil HAW, Seagroatt V, Betteridge DJ, Cooper MP, Durrington PN, Miller JP, et al. Established and emerging coronary risk factors in patients with heterozygous familial. hypercholesterolaemia. Heart. 2004; 90: 1431–7
   PubMed Web of Science ®Google Scholar
• Rodriguez G, Bertolini S, Nobili F, Arrigo A, Masturzo P, Elicio N, et al. Regional cerebral blood flow in familial hypercholesterolaemia. Stroke. 1994; 25: 831–6
   PubMed Web of Science ®Google Scholar
• Hopkins PN, Stephenson S, Wu LL, Riley WA, Xin Y, Hunt SC. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2001; 87: 547–53
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. Ann Rev Biochem. 1983; 52: 223–61
   PubMed Web of Science ®Google Scholar
• Jansen AC, van Aalst-Cohen ES, Tanck MW, Cheng S, Fontecha MR, Li J, et al. Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2005; 25: 1475–81
   PubMed Web of Science ®Google Scholar
• Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ. 1992; 305: 15–9
   PubMed Web of Science ®Google Scholar
• Ravnskov U, Rosch PJ, Sutter MC, Houston MC. Should we lower cholesterol as much as possible?. BMJ 2006; 332: 1330–2
   PubMed Web of Science ®Google Scholar
• Solomon H, Samarasinghe YP, Feher MD, Man J, Rivas-Toro H, Lumb PJ, et al. Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract. 2006; 60: 141–5
   PubMed Web of Science ®Google Scholar
• Kenis I, Tartakover-Matalon S, Cherepnin N, Drucker L, Fishman A, Pomeranz M, et al. Simvastatin has deleterious effects on human first trimester placental explants. Hum Reprod. 2005; 20: 2866–72
   PubMed Web of Science ®Google Scholar
• Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med. 2004; 350: 1579–82
   PubMed Web of Science ®Google Scholar
• Marzoa-Rivas R, Crespo-Leiro MG, Paniagua-Marin MJ, Llinares-Garcia D, Muniz-Garcia J, Aldama-Lopez G, et al. Safety of statins when response is carefully monitored: a study of 336 heart recipients. Transplant Proc. 2005; 37: 4071–3
   PubMed Web of Science ®Google Scholar
• Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. Biofactors 2005; 25: 147–52
   PubMed Web of Science ®Google Scholar
• Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol. 2004; 57: 525–8
   PubMed Web of Science ®Google Scholar
• Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Neaton J, et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation. 1992; 86: 1046–60
   PubMed Web of Science ®Google Scholar
• Sijbrands EJG, Westendorp RGJ, Defesche JD, de Meier PHEM, Smelt AHM, Kastelein JJP. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. Br Med J. 2001; 322: 1019–23
   PubMed Web of Science ®Google Scholar
• Neil HAW, Hawkins MM, Durrington PN, Betteridge DJ, Capps NE, Humphries SE; Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis. 2005;179:293–7.
   PubMed Web of Science ®Google Scholar
• Ravnskov U. Quotation bias in reviews of the diet-heart idea. J Clin Epidemiol. 1995; 48: 713–9
   PubMed Web of Science ®Google Scholar